Record citatie

APA (7e ed.) Bronvermelding
Touzeau, C., Perrot, A., Roussel, M., Karlin, L., Benboubker, L., Jacquet, C., . . . Moreau, P. (2022). All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: Final results of the phase II IFM 2013-06 study. Ferrata Storti Foundation.
Chicago (17e ed.) Bronvermelding
Touzeau, Cyrille, et al. All-oral Triplet Combination of Ixazomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-eligible Multiple Myeloma Patients: Final Results of the Phase II IFM 2013-06 Study. Ferrata Storti Foundation, 2022.
MLA (9e ed.) Bronvermelding
Touzeau, Cyrille, et al. All-oral Triplet Combination of Ixazomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-eligible Multiple Myeloma Patients: Final Results of the Phase II IFM 2013-06 Study. Ferrata Storti Foundation, 2022.
Let op: Deze citaties zijn niet altijd 100% accuraat.